https://mindmedicinelaw.com/briefing/fda-s-2026-psychedelic-drug-trial-guidance-policy-and-research-impact-20260912-41311The Psychedelic Journalen2026-09-12T22:04:14.601776+00:00FDA’s 2026 Psychedelic Drug Trial Guidance: Policy and Research Impactfda psychedelic guidance, clinical trial design, psychedelic research regulation, safety monitoring, trial endpoints, mdma trials, psilocybin regulation, diversity in trials, legal risk, drug development standardshttps://mindmedicinelaw.com/briefing/fda-s-new-psychedelic-framework-policy-and-clinical-impacts-us-2026-20260911-41405The Psychedelic Journalen2026-09-13T15:03:20.558224+00:00FDA’s New Psychedelic Framework: Policy and Clinical Impacts (US, 2026)fda psychedelic framework, psychedelic clinical trials, us psychedelic regulation, integration protocols, clinical trial design, psychedelic therapy policy, research compliance, clinic certification, drug development standards, patient safetyhttps://mindmedicinelaw.com/briefing/psilocybin-earns-second-fda-breakthrough-for-chemo-neuropathy-20260911-41054The Psychedelic Journalen2026-09-11T22:05:35.423772+00:00Psilocybin Earns Second FDA Breakthrough for Chemo Neuropathypsilocybin, fda breakthrough therapy, chemotherapy-induced neuropathy, definium, clinical trials, psychedelic medicine, oncology, drug development, regulatory policyhttps://mindmedicinelaw.com/briefing/fda-public-hearing-on-psychedelic-therapies-policy-signals-for-u-s-stakeholders-20260911-41055The Psychedelic Journalen2026-09-11T22:05:14.521758+00:00FDA Public Hearing on Psychedelic Therapies: Policy Signals for U.S. Stakeholdersfda public hearing, psychedelic therapies, federal policy, clinical trials, mdma, psilocybin, drug scheduling, risk management, implementation barriers, regulatory guidancehttps://mindmedicinelaw.com/briefing/optimi-health-s-200-participant-psilocybin-depression-trial-canada-s-expanding-c-20260910-41057The Psychedelic Journalen2026-09-11T22:06:03.090766+00:00Optimi Health’s 200-Participant Psilocybin Depression Trial: Canada’s Expanding Clinical Landscapepsilocybin depression trial, optimi health, canada clinical trials, psychedelic research, health canada, private sector trials, regulatory policy, clinical trial risks, psychedelic therapy, major depressive disorderhttps://mindmedicinelaw.com/briefing/fda-s-psychedelic-drug-framework-policy-and-clinical-implications-us-2026-20260910-41056The Psychedelic Journalen2026-09-11T22:04:56.383749+00:00FDA’s Psychedelic Drug Framework: Policy and Clinical Implications (US, 2026)fda psychedelic framework, psychedelic drug regulation, clinical trial standards, policy implications, mdma and psilocybin trials, post-market surveillance, therapist training, state-federal policy, integration protocolshttps://mindmedicinelaw.com/briefing/subjective-effects-in-psychedelic-trials-policy-and-clinical-implications-20260909-41132The Psychedelic Journalen2026-09-12T15:03:45.282612+00:00Subjective Effects in Psychedelic Trials: Policy and Clinical Implicationspsychedelic therapy, subjective effects, clinical trial design, regulatory policy, non-hallucinogenic analogs, therapeutic mechanisms, FDA guidance, insurance reimbursement, psychedelic experience, neuroscience